Ozempic becomes the first GLP-1 treatment option for people with type 2 diabetes and chronic kidney disease Mario Tama/Getty The Food and Drug Administration has approved Ozempic to reduce the ...

Chronic kidney disease affects about 37 million adults in the United States and is expected to rise. It is a common ...

The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...

The Food and Drug Administration approved Ozempic to be used to lessen the risk of kidney disease from getting worse, end-stage kidney disease and cardiovascular disease-caused death for patients ...

which started in 2019 and followed participants for an average of about 3 years. The new indications, approved Tuesday by the FDA, make Ozempic the most broadly indicated drug in its class ...

In comparison, placebo groups saw weight reductions of only 3 ... mg weekly. Common side effects include nausea, vomiting, diarrhea, and constipation. Consult your healthcare provider or the ...

Ozempic, the blockbuster GLP-1 drug that was ... drugmaker Novo Nordisk said Tuesday. A Phase 3 clinical trial found that injections of the semaglutide medication once weekly reduced the risk ...